Mexiletine
Test Mnemonic
MEX
CPT Codes
- 80299 - QTY (1)
LOINC ®
3819-0
Aliases
- Mexitil
Performing Laboratory
ARUP
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | No additive (Red) | Refrigerated | Pre-dose (trough) draw - At a steady state concentration. Refer to Special Information. Do not use serum separator tubes. Separate serum from cells within 2 hours of collection and transfer to standard aliquot tube. |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Plasma | EDTA (Lavender) | Refrigerated | Pre-dose (trough) draw - At a steady state concentration. Refer to Special Information. Do not use plasma separator tubes. Separate plasma from cells within 2 hours of collection and transfer to standard aliquot tube. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.5 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | After separation from cells: 2 days |
| Refrigerated | After separation from cells: 5 days |
| Frozen | After separation from cells: 2 months |
Days Performed
Mon, Thu, Sat
Turnaround Time
2 - 9 days
Methodology
| Name | Description |
|---|---|
| Quantitative Liquid Chromatography - Tandem Mass Spectrometry |
Reference Range
| Mexiletine | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Therapeutic Range: 0.5 - 2.0 ug/mL | Years | 99 Years | Critical | Toxic: >2.0 | ug/mL |
Special Info
Draw specimen prior to next dose - at steady state concentration. Unacceptable conditions: Whole blood, gel separator tubes, light blue (sodium citrate), or yellow (SPS or ACD Solution) tubes. This test is New York DOH approved.
Clinical Info
Used to optimize drug therapy and monitor patient adherence. The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause hypotension, tremor and cardiac abnormalities.